uniQure

^{Priced, Nasdaq: QURE}

Biotech developing gene therapies for the treatment of orphan diseases.

Industry: Health Care

First Day Return: -14.1%

QURE

Biotech developing gene therapies for the treatment of orphan diseases.

IPO News for uniQure

Looking to fight Leukemia: Syros Pharmaceuticals files for a $69 million IPO 06/03/16
Gene therapy biotech Xenon Pharmaceuticals sets terms for $44 million IPO 10/06/14
Rare disease biotech Xenon Pharmaceuticals files for a $52 million IPO 09/10/14

IPO Data
IPO Date	02/04/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$92
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.uniqure.com
Headquarters	Amsterdam, Netherlands
Founded	1998
Employees at IPO	87

IPO News for uniQure

uniQure (QURE) Performance